Driving Africa's Vaccine Independence: Aspen and Africa CDC in Groundbreaking Talks

The Africa CDC and Aspen Pharmacare are in discussions to create a framework for local vaccine production in Africa. This move aims to reduce the continent's dependency on imports, enhance health security, and build viable markets for African-made vaccines as a response to COVID-19-related disruptions.

The African Union's public health agency and Aspen Pharmacare, a South African pharmaceutical giant, are negotiating a long-term strategy to bolster vaccine production within Africa. The initiative follows exposure of the continent's dependency on vaccine imports during the COVID-19 pandemic.

The Africa Centres for Disease Control and Prevention (Africa CDC) announced the collaboration on Tuesday, revealing that the talks focus on creating sustainable markets for vaccines produced in Africa, with an aim to enhance health security and reduce reliance on foreign imports—a critical issue highlighted during recent supply disruptions.

This partnership intends to tackle import dependence by selecting priority vaccine antigens and developing local manufacturing capacity. Africa CDC Director General Jean Kaseya emphasized the importance of this step in realizing Africa's vaccine manufacturing aspirations, while Aspen's Chief Executive, Stephen Saad, highlighted the company's readiness to meet the continent's needs through its investment in sterile manufacturing and supply chain infrastructure.